BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 26744866)

  • 1. Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
    Zou Y; Guo CG; Zhang MM
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4751-61. PubMed ID: 26744866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small interfering RNA targeting vascular endothelial growth factor efficiently inhibits growth of VX2 cells and VX2 tumor model of hepatocellular carcinoma in rabbit by transarterial embolization-mediated siRNA delivery.
    Zou Y; Guo CG; Yang ZG; Sun JH; Zhang MM; Fu CY
    Drug Des Devel Ther; 2016; 10():1243-55. PubMed ID: 27069355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Wang B; Xu H; Gao ZQ; Ning HF; Sun YQ; Cao GW
    Acta Radiol; 2008 Jun; 49(5):523-9. PubMed ID: 18568538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Argonaute 2 promotes angiogenesis via the PTEN/VEGF signaling pathway in human hepatocellular carcinoma.
    Ye ZL; Huang Y; Li LF; Zhu HL; Gao HX; Liu H; Lv SQ; Xu ZH; Zheng LN; Liu T; Zhang JL; Jin HJ; Qian QJ
    Acta Pharmacol Sin; 2015 Oct; 36(10):1237-45. PubMed ID: 25937637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of preoperative transcatheter arterial chemoembolization on angiogenesis of hepatocellular carcinoma cells.
    Xiao EH; Guo D; Bian DJ
    World J Gastroenterol; 2009 Sep; 15(36):4582-6. PubMed ID: 19777619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
    Zhang L; Liu FY; Fu JX; Duan F; Fan QS; Wang MQ
    Int J Clin Exp Pathol; 2014; 7(11):7775-81. PubMed ID: 25550815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of hepatocellular carcinoma growth and angiogenesis by dual silencing of NET-1 and VEGF.
    Wu YY; Chen L; Wang GL; Zhang YX; Zhou JM; He S; Qin J; Zhu YY
    J Mol Histol; 2013 Aug; 44(4):433-45. PubMed ID: 23636606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of VEGF inhibits human osteosarcoma angiogenesis and promotes cell apoptosis via VEGF/PI3K/AKT signaling pathway.
    Peng N; Gao S; Guo X; Wang G; Cheng C; Li M; Liu K
    Am J Transl Res; 2016; 8(2):1005-15. PubMed ID: 27158386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentivirus-mediated shRNA interference targeting vascular endothelial growth factor inhibits angiogenesis and progression of human pancreatic carcinoma.
    Zhao X; Zhu DM; Gan WJ; Li Z; Zhang JL; Zhao H; Zhou J; Li DC
    Oncol Rep; 2013 Mar; 29(3):1019-26. PubMed ID: 23254994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H₂₂ murine hepatocarcinoma model.
    Sui W; Zhang Y; Wang Z; Wang Z; Jia Q; Wu L; Zhang W
    Oncol Rep; 2014 May; 31(5):2252-60. PubMed ID: 24647425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. siRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo.
    Raskopf E; Vogt A; Sauerbruch T; Schmitz V
    J Hepatol; 2008 Dec; 49(6):977-84. PubMed ID: 18845354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
    Sergio A; Cristofori C; Cardin R; Pivetta G; Ragazzi R; Baldan A; Girardi L; Cillo U; Burra P; Giacomin A; Farinati F
    Am J Gastroenterol; 2008 Apr; 103(4):914-21. PubMed ID: 18177453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ShRNA knock-down of CXCR7 inhibits tumour invasion and metastasis in hepatocellular carcinoma after transcatheter arterial chemoembolization.
    Zhao ZW; Fan XX; Song JJ; Xu M; Chen MJ; Tu JF; Wu FZ; Zhang DK; Liu L; Chen L; Ying XH; Ji JS
    J Cell Mol Med; 2017 Sep; 21(9):1989-1999. PubMed ID: 28429395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 antagonist AMD3100 enhances therapeutic efficacy of transcatheter arterial chemoembolization in rats with hepatocellular carcinoma.
    Lei HW; Huang BR; Cai J; Li CM; Shang CB; Liao ZY; Wan ZD
    Kaohsiung J Med Sci; 2022 Aug; 38(8):781-789. PubMed ID: 35467082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor.
    Deng G; Zhao DL; Li GC; Yu H; Teng GJ
    Cardiovasc Intervent Radiol; 2011 Aug; 34(4):824-32. PubMed ID: 21671151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF Silencing Inhibits Human Osteosarcoma Angiogenesis and Promotes Cell Apoptosis via PI3K/AKT Signaling Pathway.
    Zhao J; Zhang ZR; Zhao N; Ma BA; Fan QY
    Cell Biochem Biophys; 2015 Nov; 73(2):519-525. PubMed ID: 27352347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization.
    Bao Y; Feng WM; Tang CW; Zheng YY; Gong HB; Hou EG
    Hepatogastroenterology; 2012; 59(117):1566-8. PubMed ID: 22456329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Intratumoral microvessel density and expression of vascular endothelial growth factor in hepatocellular carcinoma after chemoembolization].
    Shao G; Wang J; Zhou K; Yan Z
    Zhonghua Gan Zang Bing Za Zhi; 2002 Jun; 10(3):170-3. PubMed ID: 12113668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the changes in microvessel density in hepatocellular carcinoma following transcatheter arterial chemoembolization.
    Yi J; Liao X; Yang Z; Li X
    J Tongji Med Univ; 2001; 21(4):321-2, 331. PubMed ID: 12539559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3.
    Zhou Y; Li Y; Xu S; Lu J; Zhu Z; Chen S; Tan Y; He P; Xu J; Proud CG; Xie J; Shen K
    Int J Cancer; 2020 Mar; 146(5):1383-1395. PubMed ID: 31286509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.